A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)Christopher R. Cogle, John R. Wingard, Leslie Pettiford et al.|Blood|2012Cited by 0